Efficacy Evaluation Of Neoadjuvant Chemotherapy For TEC Regimen In HER-2 Negative Breast Cancer

BackgroundNeoadjuvant chemotherapy for breast cancer(NAC)is the standard treatment for patients with locally advanced breast cancer and is currently used in patients with early stage breast cancer.Anthracyclines combined with paclitaxel are the first-line neoadjuvant chemotherapy regimen for breast cancer,and the prognosis of breast cancer is associated with the response to NAC.It is unclear for us to know which type of patients is the most suitable for the TEC regimen.To understand the characteristics of patients who are the most suitable for TEC regimen,this paper mainly studied the efficacy and effect factors of TEC regimen in patients with HER-2 negative breast cancer.ObjectiveThis study aimed to evaluate the efficacy of neoadjuvant chemotherapy with TEC regimen in patients with HER-negative breast cancer.We collected relevant clinical data to explore the p CR rate of TEC regimens and to find out the relevant characteristics which are the mostsuitable for neoadjuvant chemotherapy with TEC regimen,and to provide support for clinical work decisions.MethodsThis study collected the data of breast cancer patients admitted to the Department of Endocrine Breast Surgery,the First Affiliated Hospital of Chongqing Medical University from February 2017 to December 2018.A total of 137 patients were included in the study according to inclusion criteria and exclusion criteria.All patients included in the analysis were pathologically confirmed to have breast cancer and HER-2 negatively.None of them had received any cancer treatment,including surgery,chemotherapy,radiotherapy and endocrine therapy.These patients were treated with TEC regimen for 4 courses.We collected and recorded complete clinical data for each patient,including: age,menstrual status,tumor diameter,pathological type,ER status,Pg R status,Ki67 status,HER-2 status,Whether or not lymph node metastasis,bone metastasis and distant visceral metastasis.We used p CR as a dependent variable,the age,menstrual status,tumor size,lymphatic metastasis,pathological type,HR status,and Ki67 status was included as an independent variable for binary logistic regression analysis.Results1.The total effective rate of the TEC regimens was 91.24%,the ineffective rate was 8.76%,and the p CR rate was 9.49%.2.The p CR rate of HR negative/HER-2 negative was 15.90%,and the p CR rate of HR positive/HER-2 negative was 6.45%.The clinical effective rate of HR negative/HER-2 negative was 88.64%,and the clinical effective rate of HR positive/HER-2 negative was 92.47%.3.After binary logistic regression analysis,the results showed that HR status was the influencing factor affecting the p CR rate of neoadjuvant chemotherapy in TEC regimen.HR-negative patients were more likely to achieve p CR status via TEC regimen.Conclusions1.In NAC,the clinical effective rate of TEC regimen in the treatment of HER-2 negative breast cancer patients was 91.24%,p CR rate was9.49%.For patients with HER-2 negative,TEC regimen chemotherapy can be considered before surgery to achieve Clinical remission,even p CR.2.For patients with HER-2 negative breast cancer,binary logistic regression analysis showed that HR status was the influencing factor of p CR rate.It is recommended that HER-2 negative patients with HR negative choose TEC regimen neoadjuvant chemotherapy.3.The p CR rate of triple-negative breast cancer(HR negative/HER-2negative)is 15.90%,p CR rate of HR positive/HER-2 negative is 6.45%,and triple-negative breast cancer has a higher p CR rate.However,the three-negative breast cancer has strong invasiveness and is more prone to disease progression during NAC,the probability of occurrence is 11.36%.Therefore,monitoring should be strengthened during the NAC.